EA201501177A1 - Фармацевтические композиции - Google Patents

Фармацевтические композиции

Info

Publication number
EA201501177A1
EA201501177A1 EA201501177A EA201501177A EA201501177A1 EA 201501177 A1 EA201501177 A1 EA 201501177A1 EA 201501177 A EA201501177 A EA 201501177A EA 201501177 A EA201501177 A EA 201501177A EA 201501177 A1 EA201501177 A1 EA 201501177A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
compositions
present
disease
treating
Prior art date
Application number
EA201501177A
Other languages
English (en)
Inventor
Фолькер Шульце
Михаэль Брюнинг
Детлеф Штёккигт
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201501177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201501177A1 publication Critical patent/EA201501177A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим композициям замещенных триазолопиридиновых соединений общей формулы (I), как описано и определено в настоящей заявке, к способам получения указанных композиций и к применению композиций для лечения или профилактики заболевания.
EA201501177A 2013-06-06 2014-06-05 Фармацевтические композиции EA201501177A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170754 2013-06-06
PCT/EP2014/061711 WO2014195408A1 (en) 2013-06-06 2014-06-05 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EA201501177A1 true EA201501177A1 (ru) 2016-06-30

Family

ID=48569985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501177A EA201501177A1 (ru) 2013-06-06 2014-06-05 Фармацевтические композиции

Country Status (35)

Country Link
US (1) US20160120854A1 (ru)
EP (1) EP3003381B1 (ru)
JP (1) JP2016523229A (ru)
KR (1) KR20160018513A (ru)
CN (1) CN105263526A (ru)
AP (1) AP2015008890A0 (ru)
AR (1) AR096469A1 (ru)
AU (1) AU2014276870A1 (ru)
BR (1) BR112015030292A2 (ru)
CA (1) CA2914439A1 (ru)
CL (1) CL2015003535A1 (ru)
CR (1) CR20150641U (ru)
CU (1) CU24283B1 (ru)
CY (1) CY1119666T1 (ru)
DK (1) DK3003381T3 (ru)
DO (1) DOP2015000295A (ru)
EA (1) EA201501177A1 (ru)
ES (1) ES2652149T3 (ru)
HK (1) HK1219906A1 (ru)
HR (1) HRP20171888T1 (ru)
HU (1) HUE034883T2 (ru)
LT (1) LT3003381T (ru)
MA (1) MA38642A1 (ru)
NI (1) NI201500172A (ru)
NO (1) NO3003381T3 (ru)
PE (1) PE20152028A1 (ru)
PH (1) PH12015502703A1 (ru)
PL (1) PL3003381T3 (ru)
PT (1) PT3003381T (ru)
RS (1) RS56666B1 (ru)
SG (1) SG11201509114TA (ru)
SI (1) SI3003381T1 (ru)
TN (1) TN2015000524A1 (ru)
UY (1) UY35600A (ru)
WO (1) WO2014195408A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160156A1 (es) * 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP5128948B2 (ja) * 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
CN101125124B (zh) * 2006-08-16 2011-04-20 沈阳药科大学 一种亲脂性药物固体分散体的制备方法
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
CN102626384A (zh) * 2012-04-12 2012-08-08 临沂大学 一种姜黄素混悬剂及其制备方法

Also Published As

Publication number Publication date
KR20160018513A (ko) 2016-02-17
JP2016523229A (ja) 2016-08-08
DOP2015000295A (es) 2016-03-15
CU24283B1 (es) 2017-11-07
NO3003381T3 (ru) 2018-02-10
WO2014195408A1 (en) 2014-12-11
CN105263526A (zh) 2016-01-20
CU20150170A7 (es) 2016-03-31
CA2914439A1 (en) 2014-12-11
HUE034883T2 (hu) 2018-03-28
DK3003381T3 (en) 2017-12-11
HK1219906A1 (zh) 2017-04-21
LT3003381T (lt) 2017-12-27
HRP20171888T1 (hr) 2018-01-12
BR112015030292A2 (pt) 2017-07-25
TN2015000524A1 (en) 2017-04-06
AU2014276870A1 (en) 2015-11-19
AP2015008890A0 (en) 2015-11-30
SI3003381T1 (en) 2018-01-31
CL2015003535A1 (es) 2016-07-08
EP3003381B1 (en) 2017-09-13
SG11201509114TA (en) 2015-12-30
CY1119666T1 (el) 2018-04-04
MA38642A1 (fr) 2017-10-31
ES2652149T3 (es) 2018-01-31
CR20150641U (es) 2016-01-29
UY35600A (es) 2015-01-30
PL3003381T3 (pl) 2018-02-28
PE20152028A1 (es) 2016-02-07
AR096469A1 (es) 2015-12-30
RS56666B1 (sr) 2018-03-30
EP3003381A1 (en) 2016-04-13
PT3003381T (pt) 2017-12-20
NI201500172A (es) 2016-01-06
PH12015502703A1 (en) 2016-03-14
US20160120854A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201690844A1 (ru) Ингибиторы gsk-3
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201500931A1 (ru) Производные пиридин-4-ила
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201591451A1 (ru) Модуляторы flap
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
EA201891804A1 (ru) Тетрациклиновые соединения
CR20160016A (es) Pirazolpiridinas sustituidas
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования